Table 1.
Basic Clinical and Molecular Characteristics of Patients Characteristics
| Clinical Characteristics | All Patients (n=148) | Groups | P value* | ||
|---|---|---|---|---|---|
| Target Drug Group (n=72) | Combination Therapy Group (n=76) | ||||
| Gender | |||||
| Male | 54 (36.5) | 23 | 31 | 0.264 | |
| Female | 94 (63.5) | 49 | 45 | ||
| Age | |||||
| >60 years | 62 (41.9) | 32 | 30 | 0.540 | |
| ≤60 years | 86 (58.1) | 40 | 46 | ||
| Pathological type | |||||
| Adenocarcinoma | 135 (91.2) | 66 | 69 | 0.851 | |
| Non-adenocarcinoma | 13 (8.8) | 6 | 7 | ||
| ECOG PS | |||||
| 0–1 | 115 (77.7) | 59 | 56 | 0.228 | |
| 2 | 33 (22.3) | 13 | 20 | ||
| Smoking history | |||||
| Yes | 41 (27.7) | 19 | 22 | 0.728 | |
| No | 107 (72.3) | 53 | 54 | ||
| Family history | |||||
| Yes | 39 (26.4) | 20 | 19 | 0.701 | |
| No | 109 (73.6) | 52 | 57 | ||
| Basic disease | |||||
| Yes | 74 (50.0) | 34 | 40 | 0.511 | |
| No | 74 (50.0) | 38 | 36 | ||
| EGFR mutation: | |||||
| Exon 19 deletion | 67 (45.3) | 34 | 33 | 0.887 | |
| Exon 21L858R | 72 (48.6) | 34 | 38 | ||
| Others | 9 (6.1) | 4 | 5 | ||
| WBRT | |||||
| Yes | 76 (51.4) | - | - | - | |
| No | 72 (48.6) | - | - | - | |
| Type of EGFR-TKIs: | |||||
| Icotinib | 116 (78.4) | 53 | 63 | 0.376 | |
| Gefitinib | 30 (20.3) | 18 | 12 | ||
| Erlotinib | 2 (1.4) | 1 | 1 | ||
| Line of treatment of EGFR-TKI: | |||||
| First line | 122 (82.4) | 63 | 59 | 0.115 | |
| Second line or more | 26 (17.6) | 9 | 17 | ||
| Extracranial metastases: | |||||
| Yes | 105 (70.9) | 50 | 55 | 0.695 | |
| No | 43 (29.1) | 22 | 21 | ||
Note: *Chi-square detection values for target drug group and combination therapy group.